

Health Technology Clinical Committee

Date: July 21, 2023
Time: 8:00 a.m. – 1:30 p.m.
Location: Webinar
Adopted: November 17, 2023

Meeting materials and transcript are available on the [HTA website](#).

HTCC Minutes

Members present: John Bramhall, MD, PhD; Clinton Daniels, DC, MS; Janna Friedly, MD, MPH; Chris Hearne, DNP, MPH; Conor Kleweno, MD; Christoph Lee, MD, MS; Laurie Mischley, ND, MPH, PhD; Sheila Rege, MD; Jonathan Sham, MD; Tony Yen, MD

Clinical expert: Brian Liem, MD

HTCC Formal Action

1. **Welcome and Chair remarks:** Dr. Rege, chair, called the meeting to order; members present constituted a quorum.
2. **HTA program updates:** Josh Morse, program director, presented HTCC meeting protocols and guidelines.
3. **Hyaluronic acid/platelet-rich plasma**
 - *For Agency Medical Director presentation, vendor report, and HTCC initial voting information on HA/PRP, view [July 21 meeting materials](#).*

HTCC coverage vote and formal action:

Committee decision

Based on the deliberations of key health outcomes, the committee decided that it had the most complete information: a comprehensive and current evidence report, public comments, and state agency utilization information. The committee discussed and voted separately on the evidence for the use of HA and PRP for knee and hip osteoarthritis. The committee decided that the current evidence on HA and PRP for knee and hip osteoarthritis was sufficient to determine non-coverage. The committee considered the evidence, public comment and expert input, and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

Based on these findings, the committee voted to not cover HA/PRP for knee or hip osteoarthritis.

	Not covered	Covered under certain conditions	Covered unconditionally
HA for knee osteoarthritis	9	0	0

Final

Washington – Health Technology Clinical Committee

HA for hip osteoarthritis	9	0	0
PRP for knee osteoarthritis	5	4	0
PRP for hip osteoarthritis	9	0	0

Discussion

The committee reviewed and discussed the available studies for use of HA and PRP for knee and hip osteoarthritis. Details of study design, inclusion criteria, outcomes and other factors affecting study quality were discussed. A majority of committee members found the evidence sufficient to determine that use of HA and PRP for knee and hip osteoarthritis to be unproven for being safer, more effective, or more cost-effective than comparators.

Action

The committee checked for availability of a Centers for Medicare and Medicaid Services (CMS) national coverage decision (NCD). Based on the information provided in the systematic review, there is no NCD for hyaluronic acid or platelet-rich plasma for the treatment of knee or hip osteoarthritis.

The committee discussed clinical guidelines identified from the following organizations:

- American Academy of Orthopaedic Surgeons, 2022, *Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition*
- American College of Rheumatology (ACR), 2020, *Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee*
- Veterans Affairs/Department of Defense, 2020, *Clinical practice guideline for the non-surgical management of hip & knee osteoarthritis*
- Phillips et al., 2021, *A Systematic Review of Current Clinical Practice Guidelines on Intra-articular Hyaluronic Acid, Corticosteroid, and Platelet-Rich Plasma Injection for Knee Osteoarthritis*

The recommendations of the guidelines vary. The committee's determination is consistent with the noted guidelines.

HTA staff will prepare a findings and decision document on use of HA/PRP for the treatment of knee and hip osteoarthritis for public comment to be followed by consideration for final approval at the next committee meeting.

4. Previous meeting business:

Vote on stereotactic body radiation therapy findings and decision:

Action: Six committee members voted on draft SBRT findings and decision with renal cancer language removed, which will be discussed further at a future HTCC meeting.

June 23, 2023 meeting minutes: Draft minutes reviewed. Motion made and seconded to approve the minutes as written.

Action: Seven committee members approved the June 23, 2023 meeting minutes.

5. Meeting adjourned

Final